Abstract: A mixture of new coumamidine compounds are produced by a microorganism, belonging to the genus Saccharopolyspora. The compounds have antibiotic activity against a broad spectrum of bacteria.

Abstract: The present invention, utilizing recombinant DNA technology, provides a novel method for obtaining 20-deoxotylosin from a tylosin producing microorganism. 20-deoxotylosin is useful as an antibiotic with a microbial inhibitory activity similar to tylosin.

Abstract: The AB-011 Antibiotics and the main components thereof: AB-011a and AB-011b, obtained by the controlled aerobial cultivation of Streptomyces s.p. NCIB 12629 in an aqueous nutrient cultivation medium. The AB-011 Antibiotics show a biological activity, and in particular an antifungal activity.

Abstract: Provided are gene sequences encoding tylosin biosynthetic gene products. In particular, recombinant DNA vectors comprising DNA sequences encoding the tylA, tylB, tylI and tylG activities of Streptomyces fradiae are provided. Also provided are host cells transformed with the noted vectors and a method for increasing the tylosin-producing ability of a tylosin-producing organism.

Abstract: Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Abstract: The cloning and characterization of a newly isolated gene, referred to as saf (secondary metabolism activation factor) is disclosed. This gene encodes a new amino acid polypeptide, referred to as the SAF polypeptide, which directly or indirectly modulates the expression of extracellular enzymes in Steptomyces. DNA units or fragments which encode the SAF polypeptide are also disclosed, as are vectors containing said DNA, host organisms transformed with such vectors, and processes for preparing extracellular enzymes or heterologous polypeptides by culturing such host organisms.

Abstract: The cloning and characterization of a newly isolated gene, referred to as saf (secondary metabolism activation factor) is disclosed. This gene encodes a new amino acid polypeptide, referred to as the SAF polypeptide, which directly or indirectly modulates the expression of extracellular enzymes in Streptomyces. DNA units or fragments which encode the SAF polypeptides are also disclosed, as are vectors containing said DNA, host organisms transformed with such vectors, and processes for preparing extracellular enzymes or heterologous polypeptides by culturing such host organisms.

Abstract: A method of treating lignocellulosic material with a cellulase-free endo-xylanase for delignification, brightening and viscosity improvement. The endo-xylanase is obtained by the overexpression of the xylanase gene using a cellulase-negative recombinant microorganism of the genus Streptomyces. The recombinant microorganism is produced in a homologous cloning system in which the xylanase gene is inserted into a vector plasmid to provide the hybrid plasmid that is introduced into a host cellulase-negative mutant strain and said xylanase gene, said vector plasmid and said host mutant strain are obtained from microorganisms of the genus Streptomyces.

Abstract: Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP-1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both "live" and "inactivated" are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization.

Abstract: Spiramycin antibiotic biosynthetic genes of Streptomyces ambofaciens are provided by the present invention, in addition to a variety of recombinant DNA vectors. The genes also function in other macrolide producing organisms. The genes can be used to increase or otherwise alter the macrolide antibiotic-producing ability of an organism. The present invention also provides host strains comprising mutant spiramycin biosynthetic genes which can be used to generate novel antibiotics. Also provided is a method for preparing the mutant gene comprising mutating cloned spiramycin biosynthetic DNA by transposon mutagenesis with subsequent transformation into a macrolide-antibiotic producing host and homologous recombination into its genome, to generate stable mutant cell lines.

Abstract: Salbostatin, a compound of the formula I ##STR1## acts as a glycosidase inhibitor and is suitable for use in pharmacy and in plant protection.

Abstract: An antitumor antibiotic designated BMY-42428 is produced by fermentation of Actinomadura madurae ATCC-53806. The BMY-42428 antibiotic exhibits both antimicrobial and antitumor activities.

Abstract: The carE gene of Streptomyces thermotolerans has been isolated and used to construct recombinant DNA expression vectors. The carE gene encodes 4"-O-isovaleryl acylase activity important in the biosynthesis of a number of useful antibiotics. The carE gene can be used not only to construct recombinant cells with an increased ability to produce the acylase enzyme but also to construct recombinant cells with the ability to produce novel antibiotic compounds.

Abstract: A new compound, named Substance No. 51262, may be produced by cultivating a suitable microorganism of the genus Streptomyces, especially the new strain SANK 63584 (FERM BP-958). Said compound has herbicidal and growth retardant properties.

Abstract: The present invention discloses a method for producing a novel antibiotic, 2"'-O-demethyltylosin. The novel antibiotic, utilizing recombinant DNA technology, can be produced from a transformed mutant of a tylosin producing microorganism. By transforming for example Streptomyces fradiae GS 16 with plasmid pHJL284, the transformant can produce 2"'-O-demethyltylosin. Streytomyces fradiae GS16 is a tylosin producing species that contain a mutation in the tylE gene found in the tylosin biosynthetic pathway. The tylE gene codes for demethylmacrocin 2"'-O-methyltransferase enzyme (DMOMT), the enzyme that methylates the 2-hydroxyl position of the 6-deoxyallose moiety. Plasmid pHJL284 contains the cloned tylF gene which codes for the macrocin 3"'-O-methyltransferase enzxyme (MOMT), the enzyme that methylates the 3"'-hydroxyl position, but it does not contain the tylE gene. Transformation of S.

Abstract: A novel gene conferring resistance to picromycin in Streptomyces and related organisms was cloned from a genomic library of Streptomyces felleus DNA. The novel picromycin resistance-conferring gene can be isolated on an .about.2.8 kb PvuII fragment by subcloning the restriction fragment from plasmid pOJ321. This PvuII fragment contains all of the information required for the expression of the picromycin resistant phenotype in Streptomyces. Methods for inducing resistance, as well as vectors and transformants containing the novel picromycin resistance gene, are provided.

Abstract: Xylose isomerase (XI) muteins useful in the conversion of glucose to fructose or xylose to xylulose are obtained in usable amounts by protein structural and recombinant DNA methods, including x-ray crystallography, cloning, computer graphic modeling and site-directed mutagenesis and expression of the bacterial DNA sequences encoding native procaryotic xylose isomerase. These native sequences are altered to encode the xylose isomerase muteins having improved catalytic function and/or thermostability.

Abstract: Dihydro derivatives of LL-E33288, BBM-1075 FR-900405, FR-900406, PD 114759, PD 115028, CL-1577A, CL-1577B, CL-1577D, CL-1577E and CL-1724 antibiotics/antitumor agents are disclosed and described, including the degradation product of LL-E33288 antibiotics/antitumor agents dihydro-LL-E33288-pseudoaglycone.

Abstract: An antitumor antibiotic designated BMY-41339 is produced by fermentation of certain strains of Actinomadura verrucosospora. BMY-41339 exhibits antimicrobial activity and also inhibits the growth of tumors in experimental animals.

Abstract: A culture comprising the microorganism Micromonospora echinospora ssp. calichensis DR46 (ATCC-53591), which produces complementing factor, is described and disclosed.

Abstract: A new antitumor antibiotic designated BMY-41950 is produced by fermentation of Streptomyces staurosporeus ATCC 55006 or Streptomyces hygroscopicus ATCC 53730. The BMY-41950 antibiotic exhibits both antimicrobial and antitumor activities.

Abstract: New peptide antibiotic A54145, individual A54145 components A, A.sub.1, B, B.sub.1, C, D, E and F and their pharmaceutically acceptable salts, are useful antibacterial agents which also improve growth performance in animals, especially poultry. Biologically pure cultures of the A54145-producing Streptomyces fradiae cultures NRRL 18158, NRRL 18159 and NRRL 18160 cultures and methods of making antibiotic A54145 using those cultures are also provided.

Abstract: A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.

Abstract: L-654,040 of the structure: ##STR1## is a novel antibacterial and isolated from the novel organism Streptoverticillium synroense, strain MA6011, deposited at the ATCC.

Abstract: AB-006 Antibiotics and their AB-006 and AB-006b Antibiotic components, obtained by controlled aerobic culture of Streptomyces s.p. NCIB 12425, in an aqueous nutrient culture is disclosed. The AB-006 Antibiotics show biological activity, and in particular fungicidal and insecticidal activity.

Abstract: The present invention concerns a new antibiotic substance arbitrarily denominated antibiotic A 40926 complex and its factors antibiotic A 40926 factor A, antibiotic A 40926 factor B, antibiotic A 40926 factor B.sub.0, antibiotic A 40926 factor PA and antibiotic A 40926 factor PB, a process for producing them by culturing the new strain Actinomadura sp. ATCC 39727 or an A 40926 producing variant or mutant thereof and the use of these new antibiotic substances in the treatment of infectious diseases involving microorganisms susceptible to them. The antibiotic substances of the invention are glycopeptidic substances belonging to the vancomycin class of antibiotics which have binding capacity to Acyl-D-Alanyl-D-Alanine.

Abstract: The object of this invention is to provide a method for selectively increasing the ratio of the single T-A2 major components in the T-A2 complex. More particularly, the object of this invention is a process for obtaining teicoplanin A.sub.2 selectively enriched in any of its major components, T-A2-1, T-A2-2, T-A2-3, T-A2-4 and T-A2-5 which consists in adding to the culture medium of Actinoplanes teichomyceticus nov. sp. ATCC 31121 or a mutant thereof which produces T-A2 complex through the same metabolic pathway, a selectively effective amount of an appropriate precursor.

Abstract: There is provided new antitumor antibiotic substances designated herein as BBM-1675C and BBM-1675D, said substances being produced by selective chemical hydrolysis of the bioactive components BBM-1675A.sub.1 (esperamicin A.sub.1) or BBM-1675A.sub.2 (esperamicin A.sub.2). The new antitumor antibiotics exhibit both antimicrobial activity and antitumor activity.

Abstract: An antibiotic has been isolated from fermentation of a new Streptomyces culture. The new ionophore is active as an antibacterial and anticoccidial agent.

Abstract: The present invention is directed to a new antibiotic substance denominated antibiotic A 42867 pseudoaglycon, a pharmaceutically acceptable salt thereof, a process for its preparation from antibiotic A 42867 and pharmaceutical compositions containing the new substance of the invention.

Abstract: An antibiotic F-0769 having the following properties:(1) Outer appearance: White or light yellow powder,(2) Melting point: 245.degree.-250.degree. C.,(3) Specific rotation: [.alpha.].sub.D.sup.25 =-37.5.degree. (c=1, methanol),(4) Solubility in solvents: Soluble in methanol, ethanol, acetone, chloroform, ethyl acetate and benzene; and insoluble in water and hexane,(5) Elementary analysis (found %): C:57.53, H:7.36, O:21.17, N:12.97,(6) Ultraviolet absorption spectrum (as measured in methanol: As shown in FIG. 1, .lambda.max(E.sub.1 cm.sup.1%)=213 nm (466), 286 nm (200)(7) Infrared absorption spectrum (as measured by KBr method): As shown in FIG. 2,(8) Nuclear magnetic resonance spectra (as measured in heavy chloroform): .sup.1 H-NMR spectrum is as shown in FIG. 3, and .sup.13 C-NMR spectrum is as shown in FIG. 4,(9) Distinction among basicity, acidity and neutrality: Neutral substance,(10) Amino acid analysis: As a result of the hydrolysis with 6N hydrochloric acid at 110.degree. C.

Abstract: New antibiotic A80509, its C.sub.1 -C.sub.7 -alkyl ester derivatives and salts are useful antibacterial and anticoccidial agents and improve feed efficiency and growth in animals. Methods of making A80509 by fermentation of, and a biologically pure culture of, Streptomyces mutabilis NRRL 18269 are also provided.

Abstract: The present invention relates to methods and compositions for the control and prevention of helmintic, arthropod ectoparasitic and acaridal infections, in warm-blooded animals, such as meat-producing animals, and poultry, by administering to said animals a therapeutically or prophylactically-effective amount of new agents designated LL-F28249.alpha., .beta., .gamma., .delta., .epsilon., .zeta., .eta., .theta., .iota. and .omega., or mixtures thereof. The invention also relates to methods for the control of plant nematode infestations. These novel agents are produced via a controlled conditioned microbiological fermentation using Streptomyces sp. LL-F28249, having deposit accession number NRRL 15773.

Abstract: Antibiotic LL-D42067.beta. derived by aerobic fermentation of the microorganism Actinomadura madurae subspecies simaoensis NRRL 15734, useful as an antibacterial and antiparasitic agent.

Abstract: The toxin gene encoding a protein toxic to beetles of the order Coleoptera, named M-7, has been cloned and expressed. M-7 is a novel Bacillus thuringiensis strain which has been deposited with a recognized culture repository. The microbe is now known as B. thuringiensis strain san diego.

Abstract: A process for producing unnatural penicillins and cephalosporin derivatives thereof in which peptide analogs of ACV in which the L-.alpha.-aminodipyl moiety is replaced by L-S-carboxymethyl cysteine or other obvious substituents, are reacted with cyclase, epimerase, ring expansion and hydroxylase enzymes isolated from a cell free extract of a prokaryotic organism such as S. clavuligerus. The product depends upon the presence or absence of co-factors such as ferrous ion, .alpha.-ketoglutarate, and ascorbate. In an alternative embodiment, a penicillin analog having the formula: ##STR1## may be reduced with L-cysteine to produce an analog of isopenicillin N which may be reacted with the enzyme reagent to produce the desired penicillin or cephalosporin.

Abstract: Cultivation of a strain of the microorganism Micromonospora sp. A.T.C.C. No. 53481, yields the novel antibiotic substance glyphomicin, which is a mixture of glyphomicin A and glyphomicin B.

Abstract: A novel antibiotic, A 42867, is prepared by cultivating the strain Nocardia sp. ATCC 53492, or an antibiotic A 42867-producing mutant or variant thereof, under submerged aerobic conditions in the presence of assimilable sources of carbon, nitrogen and inorganic salts. The antibiotic and its addition salts are useful in the treatment of infectious diseases and as growth promotant agents.

Abstract: This invention relates to a compound, FR-900848, having antimicrobial activity against various microorganisms, to a process for the preparation of same and to a pharmaceutical composition comprising same.

Abstract: Promoting the growth of animals with a novel compound, named annomycin, by cultivation of Streptomyces strain BS 572, DSM 3817.

Abstract: Two strains of Streptomyces were identified as Streptomyces albovinaceous. Both isolates produced an antibiotic when grown in liquid culture medium containing homogenized oats. The antibiotic (Treponemycin) was isolated from the culture broth by solvent extraction and purified. The antibiotic showed inhibitory activity against several species of bacteria, especially Treponema hyodysenteriae, the causative agent of swine dysentery. In view of the oral 50% lethal dose of 400 mg/kg and its low MIC against four strains of T. hyodysenteriae, the antibiotic has value as a swine dysentery therapeutic. The antibiotic lends itself readily to production of a tetrahydro derivative, a primary amine, a dimethyl ester and a hydrochloride esters and salts of these compounds, and hydrates of these compounds and of the esters or salts can also be produced for pharmaceutical usages.

Abstract: The present invention is a method for expressing functional polypeptides in Streptomyces using a recombinant DNA expression vector comprising a novel transcriptional- and translational- activating sequence. The novel activating sequence can be synthesized by conventional methods and used in Streptomyces expression vectors. One such vector, plasmid pFJ350, expresses and confers hygromycin resistance in Streptomyces host cells.

Abstract: This invention relates to antibiotic LL-E19020.alpha. and LL-E19020.beta. derived from the microorganism Streptomyces lydicus subspecies tanzanius NRRL 18036, which are useful as an antibacterial agent.

Abstract: This invention provides methods for increasing the growth rate of meat producing animals, for improving the efficiency of feed utilization by said meat producing animals, and for increasing lactation in lactating ruminant animals. The invention also relates to novel animal feed compositions and parenteral compositions useful in obtaining the above-described desired results.

Abstract: Antibiotic 82-85-8A, or a pharmacologically acceptable non-toxic salt thereof, having the following physicochemical properties:(1) Elementary analysis: C.sub.31 H.sub.47 N.sub.8 O.sub.10 Cl (determined by high resolution mass spectrometry)(2) Molecular weight: 726.5 (determined by field desorption mass spectrometry and calculated from elementary analysis)(3) Melting point: 162.degree.-167.degree. C. (partially immersed at 160.degree. C., completely melted at 167.degree. C., no browning)(4) Specific rotation: [.alpha.].sub.D.sup.20 =-56.degree. (c=0.24, methanol)(5) Ultraviolet absorption spectrum (in methanol): shown in FIG. 1(6) Infrared absorption spectrum (KBr): shown in FIG. 2(7) Solubility:soluble: chloroform, dichloromethane, ethyl acetate, methanol, ethanol,slightly soluble: acetone,insoluble: hexane, water;(8) Color reaction:Positive: iodine, sulfuric acid, Dragendorf reactionNegative: ninhydrin, ferric chloride(9) Nature: weakly basic substance.

Abstract: A purified isolate of an actinomycete identified as ATCC 39366 is capable of producing the antimicrobial compound CL-1957D.The antimicrobial compound CL-1957D is produced by cultivating isolate ATCC 39366 under aerobic conditions in a culture medium containing assimilable sources of carbon and nitrogen until a substantial quantity of the CL-1957D compound is produced, and subsequently isolating the CL-1957D compound.The antibiotic compound CL-1957D and pharmaceutical compositions comprising this substance together with a pharmaceutically acceptable carrier is also disclosed, as are methods of treating microbial infections in mammals, employing these pharmaceutical compositions.

Abstract: A novel subspecies of Kibdelosporangium aridum, subsp. largum (SK&F-AAD-609) produces AAD-216 antibiotics and AAD-609 antibiotics, the ADD-609 antibiotics differing from the AAD-216 antibiotics in presence of glucosamine in the glycolipid radical in place of amino glucuronic acid.

Abstract: A new substance K-259-2 having a molecular formula of C.sub.21 H.sub.18 O.sub.7, a molecular weight of 382 and an elemental analysis (%) of H: 4.50, C: 65.53 and N: 0. This substance is of interest in providing a new vasodilating agent in view of its ability to dilate the blood vessel, particularly the artery, of mammals. This substance may be obtained by fermentation of a microorganism Micromonospora sp. K-259 (FERM BP 569).

Abstract: There is presented antibiotic compounds designated as Antibiotics X-14889 A, C and D of the formulas ##STR1## wherein (for X-14889A) R.sub.1 is methyl, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is hydrogen or (for X-14889C) R.sub.1 is hydrogen, R.sub.2 is methyl, R.sub.3 is hydrogen, R.sub.4 is methyl and R.sub.5 is CO.sub.2 H or ##STR2## and the pharmaceutically acceptable salts thereof. The compounds exhibit antimicrobial activity and one of the compounds X-14889C also exhibits activity against Treponema hyodysenteriae (in vitro), Plasmodium berghei and as food efficiency enhancers in ruminants.Also presented is a process to produce the above compounds and another known component Antibiotic X-14889B.

Abstract: A novel antibiotic for combating bacteria and promoting animal growth is obtained by cultivating Streptomyces strain BA 9.